Table 3. Risk Assessment of Individual Studies Using the National Institute of Health Quality Assessment Tool for Observational Cohort and Cross-sectional Studies.
| STUDY | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Q14 | Quality Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hill18 (PROACT-II) | + | + | + | + | - | - | + | + | + | NA | + | CD | + | + | Good |
| Imai19 | + | + | NA | + | - | - | + | + | + | NA | + | CD | + | + | Fair |
| Psycholgios20 | + | + | NA | + | - | - | + | + | + | NA | - | CD | + | + | Fair |
| Hill21 (IMS-III) | + | + | + | + | + | - | + | + | + | NA | + | CD | + | - | Good |
| Inoue22 | + | + | NA | + | - | - | + | + | + | NA | + | CD | + | + | Fair |
| Yoo11 (Penumbra Pivot) | + | + | + | + | - | - | + | + | + | NA | + | CD | + | - | Fair |
| Berkhemer1 (MR-CLEAN) | + | + | + | + | - | + | + | + | + | NA | + | CD | + | + | Good |
| Espinosa de Rueda12 | + | + | + | + | - | - | + | + | + | NA | + | CD | + | + | Good |
| Goyal3 (ESCAPE) | + | + | + | + | + | + | + | + | + | NA | + | CD | + | + | Good |
| Jovin4 (REVASCAT) | + | + | - | + | + | + | + | + | + | NA | + | CD | + | + | Good |
| McTarggart23 (DEFUSE-II) | + | − | + | + | − | − | + | + | + | NA | + | CD | + | + | Fair |
| Saver5 (SWIFT-PRIME) | + | + | + | + | NA | + | + | + | + | + | + | CD | + | − | Good |
| Spiotta13 | + | − | NA | + | − | − | + | + | + | NA | + | CD | + | − | Fair |
| Kim24 | + | + | + | + | NA | − | + | + | + | NA | + | CD | + | − | Fair |
+, Yes; −, No; CD, cannot determine; NA, not applicable